GlassScriptPhysician profile
Donald Bernardini
NPI 1568643120
$102,219.83
in general payments reported to CMS, 2019-2025
64 companies · $2,437 in 2025
The $2,437 reported for 2025 was more than what 85% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $20K · 2021: $4,305 · 2022: $28K · 2023: $14K · 2024: $2,581 · 2025: $2,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,257 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,825 · Consulting Fee: $3,675 · Travel and Lodging: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,256.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,825.00 |
| Consulting Fee | $3,675.00 |
| Travel and Lodging | $1,926.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $78,739.34 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Pain Management |
| Abbott Laboratories | $5,140.42 | 2019-2025 | Proclaim, Eterna |
| Relievant Medsystems, INC. | $2,900.56 | 2019-2023 | Intracept |
| Vertos Medical, INC. | $2,470.84 | 2020-2024 | Mild Device Kit |
| Abbvie INC. | $1,562.46 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Merz North America, INC. | $1,168.54 | 2021-2023 | Xeomin |
| Southern Spine, LLC | $1,000.00 | 2022 | |
| Painteq LLC | $700.68 | 2021-2024 | Painteq |
| Saluda Medical Americas, INC. | $629.82 | 2024-2025 | Evoke |
| Allergan, INC. | $613.03 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $513.48 | 2019-2024 | Xtampza, Nucynta, Belbuca |
| Scilex Pharmaceuticals INC. | $431.14 | 2019-2024 | Ztlido |
| Vertiflex, INC. | $394.89 | 2019 | |
| Nevro Corp. | $392.27 | 2019-2024 | Senza |
| Lundbeck LLC | $380.55 | 2020-2025 | Vyepti |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Bernardini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.